brand logo

Am Fam Physician. 2024;109(5):463-464

Author disclosure: No relevant financial relationships.

Clinical Question

Is baclofen effective in achieving abstinence in patients with alcohol use disorder (AUD)?

Evidence-Based Answer

Baclofen with psychosocial therapy is modestly effective in helping patients with AUD achieve abstinence, increasing abstinent days by approximately 10%. (Strength of Recommendation [SOR]: A, systematic review and meta-analysis of randomized controlled trials and cohort studies.) A total of 40% to 50% of patients can achieve or maintain abstinence at 1 year after treatment initiation. (SOR: B, several small cohort studies.) Baclofen does not show evidence of worsening liver function in patients with cirrhosis.

Evidence Summary

A 2023 Cochrane review evaluated 17 randomized controlled trials (n = 1,818) investigating the use of baclofen in patients with AUD.1 Studies assessed baclofen compared with placebo, no treatment, and other pharmacologic therapies for achieving alcohol abstinence or reduced consumption in patients with AUD. The mean age of participants was 46.5 years, and 70% were men. Three studies recruited people with severe liver disease. In all but one study, patients received psychosocial therapy. Treatment duration was at least 4 weeks, with a mean duration of 16 weeks. The daily baclofen dosage ranged from 30 to 300 mg. Most studies started at fixed dosages of 5 mg three times per day and increased to a total daily dosage of 30 to 80 mg. When compared with placebo, baclofen was found to increase the percentage of abstinent days in patients taking low-dose daily regimens of 30 mg or less (mean difference [MD] = 10.6%; 95% CI, 0.8 to 20.4; eight studies; 583 participants) and high-dose regimens of 100 mg or more (MD = 11.1%; 95% CI, 4.4 to 17.8; three studies; 465 participants). There were no differences in abstinent days between patients taking baclofen vs. placebo among studies using medium dosages of 30 to 100 mg daily (MD = 7.1%; 95% CI, −3.1 to 17.4; five studies; 225 participants). Compared with placebo, baclofen was found to decrease the risk of relapse in people no longer drinking alcohol (risk ratio = 0.87; 95% CI, 0.77 to 0.99; 12 studies; 1,057 participants). There were no differences in the risk of relapse at the end of treatment between low, medium, and high dosages compared with placebo. Moderate to substantial heterogeneity was noted between the included studies.

Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to or email:

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Clinical Inquiries published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2024 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.